Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%

According to the Zhitong Finance APP, Wolwo Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 853 million yuan, a year-on-year increase of 16.86%. The net profit attributable to shareholders of the listed company was 345 million yuan, a year-on-year increase of 26.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 340 million yuan, a year-on-year increase of 28.92%. The basic earnings per share were 0.6587 yuan

A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit

Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solution

Wolwo Pharma has completed the Phase I clinical trial of the Aspergillus flavus puncture solution and obtained the summary report. The study shows that the drug has good safety within the set dosage range, with no serious adverse reactions occurring. Some subjects experienced delayed reactions, which may be related to the characteristics of the fungus. The specificity for each dosage exceeded 95%, and the sensitivity reached 95% at 55000 DU/mL. The researchers recommend conducting subsequent clinical studies at doses of 55000 DU/mL and above, and exploring strategies to reduce delayed reactions

Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch

Wolwo Pharma announced that it has completed the clinical trial of the "Artemisia Annua Pollen Allergen Sublingual Drops." The summary report indicates that the product has good safety in adult patients with allergic rhinitis, with the main adverse reactions being grade 1 and 2. After 2 years of treatment and monitoring after discontinuation, it has been confirmed that the drug effectively improves symptoms caused by Artemisia Annua/Artemisia Pollen and reduces the use of symptomatic medications, providing evidence for long-term clinical application

Zhongtai Securities: Maintain Wolwo Pharma "Buy" rating, steady revenue growth, core products continue to expand

Zhongtai Securities maintains a "Buy" rating for Wolwo Pharma, expecting a net profit attributable to the parent company of 318 million yuan in 2024, a year-on-year increase of 2.46%. The net profit attributable to the parent company for the first quarter of 2025 is expected to be 74 million yuan, a year-on-year decrease of 3.71%. The company's revenue growth is steady, core products continue to increase in volume, market share exceeds 80%, and the sales of Artemisia annua powder drops continue to grow, with the product line constantly expanding